Alpha-N-acetylgalactosaminidase deficiency
Dernière mise à jour 14 mars 2025
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Ask Patient
- Version audio
- Ajouter aux sources préférées sur Google
Alpha-N-acetylgalactosaminidase deficiency, also known as Schindler disease, is an inherited disorder that can affect the development of the nervous system. People with alpha-N-acetylgalactosaminidase deficiency often have distinctive facial features that can be described as "coarse" and tooth abnormalities such as widely-spaced teeth and missing teeth (hypodontia).
Sélections vidéo pour Conditions génétiquesBibliothèque vidéo
Description
Alpha-N-acetylgalactosaminidase deficiency, also known as Schindler disease, is an inherited disorder that can affect the development of the nervous system. People with alpha-N-acetylgalactosaminidase deficiency often have distinctive facial features that can be described as "coarse" and tooth abnormalities such as widely-spaced teeth and missing teeth (hypodontia).
The three types of alpha-N-acetylgalactosaminidase deficiency differ in the severity of their signs and symptoms and the age at which they first appear. The signs and symptoms of alpha-N-acetylgalactosaminidase deficiency can vary, even among members of the same family.
Type I is the most severe form of this condition. Babies with alpha-N-acetylgalactosaminidase deficiency type I appear healthy at birth. However, by late infancy, these babies typically have trouble meeting normal developmental milestones. By the age of 2 years, individuals with type I begin to lose skills that they had already acquired (developmental regression). Individuals with type I often experience weak muscle tone (hypotonia), vision and hearing loss, and seizures. During early childhood, children with type I typically lose awareness of their surroundings and eventually become unresponsive.
Alpha-N-acetylgalactosaminidase deficiency type II is the least severe form. Type II is typically diagnosed in adulthood. Affected individuals may have mild cognitive impairment and hearing loss caused by abnormalities of the inner ear (sensorineural hearing loss). They may also experience a loss of sensation or muscle weakness in the extremities (peripheral neuropathy). Clusters of enlarged blood vessels that form small, dark red spots on the skin (angiokeratomas) are a characteristic feature of alpha-N-acetylgalactosaminidase deficiency type II.
Type III is the intermediate form of alpha-N-acetylgalactosaminidase deficiency. People with type III may show a variety of signs and symptoms, including developmental, speech, and language delays; seizures that begin in infancy; and features of autism spectrum disorder that appear in childhood. Autism spectrum disorder is characterised by impaired communication and socialization skills. People with type III may also have skeletal signs and symptoms, such as pain in the lower back, hips, and knees. Wear on the cartilage (disks) and bones of the neck (cervical spondylosis) and a cyst-like collection of cerebrospinal fluid that forms in the spinal cord (syringohydromyelia) have also been reported.
Inheritance patterns
The source lists the following possible inheritance patterns: Autosomal recessive. More than one pattern can apply in different cases.
Related genes
Other names
Alpha-galactosidase B deficiency
Alpha-galNAc deficiency, Schindler type
Alpha-N-acetylgalactosaminidase deficiency
Alpha-NAGA deficiency
Angiokeratoma corporis diffusum-glycopeptiduria
GALB deficiency
Kanzaki disease
Lysosomal glycoaminoacid storage disease-angiokeratoma corporis diffusum
NAGA deficiency type I
NAGA deficiency type II
NAGA deficiency type III
Neuroaxonal dystrophy, Schindler type
Neuronal axonal dystrophy, Schindler type
Schindler disease type I
Schindler disease type II
Schindler disease type III
Related patient information and medicines

Patient information leaflet
Tests de fonction hépatique
Tests de fonction hépatique are a set of sang tests commonly done to check on the health of your liver. Changes in liver function tests give a clue as to whether your liver is under strain, inflamed, infected or diseased, and how badly. The pattern of the liver function tests can give a clue to the cause and can allow early detection of unsuspected.

Patient information leaflet
Insuffisance hépatique
Diseases of the veins in the liver Some diseases (for example, Budd-Chiari syndrom... Metabolic diseases Some rare metabolic diseases may cause acute liver failure. These include haemochromatosis Haemochromatosis , alpha-1 antitrypsin deficiency Alpha-1 antitrypsine deficiency , Wilson's disease Wilson's disease , fructose intolerance,.

Patient information leaflet
Syndrome des jambes sans repos
No treatment may be needed if symptom... Medication can ease symptoms if the condition is distressing. What is restless legs syndrome. Restless legs syndrome (RLS) is sometimes called Willis-Ekbom disease after the doctors who first described it. It is a condition where you have an urge to move your legs. This is usually caused by an uncomfortable.

Patient information leaflet
Malabsorption gastro-intestinale
Gastrointestinal malabsorption syndrome means a failure to fully absorb digested aliments from the gut (bowel) into your body. There are many different causes. Prolonged intestinal malabsorption may cause problems because of a lack of carbohydrates, proteins, fats, minerals and vitamins that are essential to keep you healthy. The treatment will.

Patient information leaflet
Bronchectasie
Bronchectasie is a problem with the lungs, where you cough up lots of phlegm, (sputum): far more than usual. It is usually caused by something that has already affected the lungs, like a bad infection; but sometimes no cause is found. It generally affects older people. There are some good treatments available to keep it under control..

Patient information leaflet
Puis-je prendre de l'acide folique et de la glucosamine ensemble ?
It is generally considered safe to take these two supplements together. Why this happens Folic acid (a B vitamin) and glucosamine (an amino sugar) are processed by the body through different pathways. They do not compete for absorption in the gut, nor do they interfere with how the liver breaks down or the kidneys remove each substance. Our.
Lectures complémentaires et références
- Alpha-N-acetylgalactosaminidase deficiency; MedlinePlus, National Library of Medicine.
- Bakker HD, de Sonnaville ML, Vreken P, Abeling NG, Groener JE, Keulemans JL, van Diggelen OP. Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: no association with neuroaxonal dystrophy? Eur J Hum Genet. 2001 Feb;9(2):91-6. doi: 10.1038/sj.ejhg.5200598.
- Blanchon YC, Gay C, Gibert G, Lauras B. A case of N-acetyl galactosaminidase deficiency (Schindler disease) associated with autism. J Autism Dev Disord. 2002 Apr;32(2):145-6. doi: 10.1023/a:1017499407910. No abstract available.
- Castro RG, Perez AMG, Curto MCR, Alvarez JC, Ferreiros AC, Cuadros AV, Bueno DM, Fernandez AJC. A New Case of Schindler Disease. Eur J Case Rep Intern Med. 2019 Oct 25;6(11):001269. doi: 10.12890/2019_001269. eCollection 2019.
- Chabas A, Duque J, Gort L. A new infantile case of alpha-N-acetylgalactosaminidase deficiency. Cardiomyopathy as a presenting symptom. J Inherit Metab Dis. 2007 Feb;30(1):108. doi: 10.1007/s10545-006-0470-1. Epub 2006 Dec 14.
- Clark NE, Garman SC. The 1.9 a structure of human alpha-N-acetylgalactosaminidase: The molecular basis of Schindler and Kanzaki diseases. J Mol Biol. 2009 Oct 23;393(2):435-47. doi: 10.1016/j.jmb.2009.08.021. Epub 2009 Aug 14.
- Desnick RJ, Wang AM. Schindler disease: an inherited neuroaxonal dystrophy due to alpha-N-acetylgalactosaminidase deficiency. J Inherit Metab Dis. 1990;13(4):549-59. doi: 10.1007/BF01799512.
- Kanda A, Tsuyama S, Murata F, Kodama K, Hirabayashi Y, Kanzaki T. Immunoelectron microscopic analysis of lysosomal deposits in alpha-N-acetylgalactosaminidase deficiency with angiokeratoma corporis diffusum. J Dermatol Sci. 2002 May;29(1):42-8. doi: 10.1016/s0923-1811(02)00005-1.
- Kanekura T, Sakuraba H, Matsuzawa F, Aikawa S, Doi H, Hirabayashi Y, Yoshii N, Fukushige T, Kanzaki T. Three dimensional structural studies of alpha-N-acetylgalactosaminidase (alpha-NAGA) in alpha-NAGA deficiency (Kanzaki disease): different gene mutations cause peculiar structural changes in alpha-NAGAs resulting in different substrate specificities and clinical phenotypes. J Dermatol Sci. 2005 Jan;37(1):15-20. doi: 10.1016/j.jdermsci.2004.09.005. Epub 2004 Dec 8.
- Kanzaki T, Yokota M, Irie F, Hirabayashi Y, Wang AM, Desnick RJ. Angiokeratoma corporis diffusum with glycopeptiduria due to deficient lysosomal alpha-N-acetylgalactosaminidase activity. Clinical, morphologic, and biochemical studies. Arch Dermatol. 1993 Apr;129(4):460-5.
- Kodama K, Kobayashi H, Abe R, Ohkawara A, Yoshii N, Yotsumoto S, Fukushige T, Nagatsuka Y, Hirabayashi Y, Kanzaki T. A new case of alpha-N-acetylgalactosaminidase deficiency with angiokeratoma corporis diffusum, with Meniere's syndrome and without mental retardation. Br J Dermatol. 2001 Feb;144(2):363-8. doi: 10.1046/j.1365-2133.2001.04028.x.
- Michalski JC, Klein A. Glycoprotein lysosomal storage disorders: alpha- and beta-mannosidosis, fucosidosis and alpha-N-acetylgalactosaminidase deficiency. Biochim Biophys Acta. 1999 Oct 8;1455(2-3):69-84. doi: 10.1016/s0925-4439(99)00077-0.
- Mohamed FE, Al Sorkhy M, Ghattas MA, Al-Zaabi N, Al-Shamsi A, Almansoori TM, Al-Gazali L, Al-Dirbashi OY, Al-Jasmi F, Ali BR. A Novel Homozygous Missense Variant in the NAGA Gene with Extreme Intrafamilial Phenotypic Heterogeneity. J Mol Neurosci. 2020 Jan;70(1):45-55. doi: 10.1007/s12031-019-01398-6. Epub 2019 Aug 29.
- Sakuraba H, Matsuzawa F, Aikawa SI, Doi H, Kotani M, Nakada H, Fukushige T, Kanzaki T. Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease). J Hum Genet. 2004;49(1):1-8. doi: 10.1007/s10038-003-0098-z. Epub 2003 Dec 19.
- Umehara F, Matsumuro K, Kurono Y, Arimura K, Osame M, Kanzaki T. Neurologic manifestations of Kanzaki disease. Neurology. 2004 May 11;62(9):1604-6. doi: 10.1212/01.wnl.0000123116.96441.34.
Historique de l'article
Article également disponible en Anglais, Allemand, Espagnol, Français, Italien, Portugais, Hindi, Hébreu, Arabe, and Suédois.
14 mars 2025 | Dernière version
1 mars 2025 | Publié à l'origine
Partagez vos pensées ou expériences avec les autres dans notre communautés de patients.
Inscrivez-vous à la newsletter Patient
Votre dose hebdomadaire de conseils de santé clairs et fiables - rédigés pour vous aider à vous sentir informé, confiant et maître de la situation.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.

